<DOC>
	<DOCNO>NCT01987765</DOCNO>
	<brief_summary>This study Post-Marketing Surveillance study Korea evaluate safety efficacy Relestat Ophthalmic Solution 0.05 % patient allergic conjunctivitis treat Relestat standard care clinical practice .</brief_summary>
	<brief_title>Safety Efficacy Relestat Ophthalmic Solution 0.05 % Allergic Conjunctivitis Korea</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients Allergic Conjunctivitis treat Relestat Ophthalmic Solution clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>